用于人乳腺癌病理检测的抗人ARD1单克隆抗体的制备

hARD1蛋白是一个乙酰基转移酶,催化蛋白质N末端的乙酰化。前期的研究发现hARD1的高表达可能作为乳腺癌的一个指标。为了制备在乳腺肿瘤组织中特异识别的抗hARD1的单克隆抗体,将纯化的全长hARD1/Histag融合蛋白(1~235aa)免疫Balb/c小鼠,获得了8个稳定的阳性单克隆细胞株,酶联免疫吸附测定(ELISA)结果表明,所得抗体的轻链均为κ型,重链为3种亚型:IgG1、IgG2a和IgG2b。在不同肿瘤组织样本中进行抗体特异性筛选,获得一个在乳腺肿瘤组织中具有相对特异性的抗hARD1单克隆抗体,为进一步将抗hARD1的单克隆抗体应用于乳腺癌的病理诊断奠定基础,同时也为进一步研究hARD1在肿瘤发生中的作用提供了重要的工具。     

猪δ冠状病毒(PDCoV)N蛋白的原核表达及多克隆抗体制备

旨在表达和纯化猪δ冠状病毒(PDCoV)N蛋白并制备该蛋白的多克隆抗体。以RT-PCR扩增PDCoV N基因并与表达载体pET-28a构建重组质粒,转化Transetta(DE3)菌株诱导表达,SDS-PAGE鉴定融合蛋白表达,以纯化的N蛋白免疫家兔制备多克隆抗体,Western blot验证兔抗血清特异性,间接ELISA测定抗血清效价。利用间接免疫荧光试验(IFA)、免疫荧光试验(IF)、流式细胞术(FCM)鉴定其诊断应用价值。重组N蛋白为可溶性表达,大小约为44 kD,制备的兔抗N蛋白抗体效价可达1∶204 800。IFA与FCM试验证实该抗体能与PDCoV特异性结合,与PEDV及TGEV无交叉反应,IF试验表明该抗体可用于检测小肠组织中的PDCoV。     

OS-9基因的融合表达、纯化及多克隆抗体制备

OS 9基因广泛表达于人体多种组织 ,该基因的表达产物可能与肿瘤的发生相关 .为获得可溶性表达的OS 9蛋白 ,制备多克隆抗体 ,深入了解OS 9基因的功能 ,将OS 9基因片段克隆入组氨酸标签融合的表达载体pET2 8a中 ,IPTG诱导 ,利用金属螯合亲和层析 (MCAC)进行纯化 ,薄层扫描及Bradford法检测纯化蛋白的纯度与含量 .免疫家兔制备多克隆抗体 ,利用间接ELISA法检测抗体效价 ,Western印迹检测抗体特异性 .经表达形式分析证明 ,融合蛋白大部分可溶 .薄层扫描分析纯度可达 90 %以上 ,Bradford法检测蛋白浓度约 0 1mg ml.抗血清效价可达 1∶32 0 0以上 ,Western印迹检测证明抗体特异性良好 .经诱导表达及纯化制备出可溶的纯度较高的OS 9蛋白产物 ,并获得高效价特异性良好的多克隆抗体     

非天然氨基酸突变的小鼠RANKL蛋白原核表达及抗血清制备

目的:研究非天然氨基酸突变的小鼠RANKL(m RANKL)蛋白的原核表达,并以表达的蛋白制备抗m RANKL蛋白的抗血清。方法:从小鼠的骨髓中提取总RNA,经PCR扩增m RANKL的胞外段,逆转录合成目的 DNA片段。将目的基因中编码第234位酪氨酸的密码子(TAT)突变成可编码非天然氨基酸p-硝基苯丙氨酸(p NO2Phe)的琥珀密码子(TAG),构建p ET28a-p NO2Phe234m RANKL重组表达载体,与p EVOL质粒共转化至表达菌E.coli BL-21(DE3),诱导表达并纯化。以纯化的蛋白免疫小鼠,制备小鼠抗m RANKL抗血清。采用ELISA测定抗血清效价,用Western Blot测定其特异性。结果:RT-PCR扩增出750bp的RANKL基因,并成功构建了p ET28a-p NO2Phe234m RANKL重组表达载体;p-硝基苯丙氨酸突变的m RANKL蛋白获得成功表达和纯化;以纯化的蛋白免疫小鼠,获得抗m RANKL抗血清,ELISA检测效价为1:6400,Western Blot结果显示该抗血清既可与p-硝基苯丙氨酸突变的m RANKL结合,也可与野生型m RANKL结合。结论:原核表达并纯化了p-硝基苯丙氨酸突变的m RANKL,制备了小鼠抗m RANKL的抗血清,为进一步研究阻断RANKL-RANK通路的新方法奠定了基础。     

人高迁移率族蛋白B1，高迁移率族蛋白B1 A box和B box的原核表达、 纯化及高迁移率族蛋白B1多克隆抗血清的制备

目的:获取重组人高迁移率族蛋白B1(HMGB1),HMGB1Abox和Bbox的纯化蛋白,制备HMGB1的多克隆抗血清。方法:采用PCR方法扩增人HMGB1,HMGB1的Abox和Bbox目的基因片段,构建原核表达载体,进行原核表达与蛋白纯化,然后用HMGB1免疫新西兰大白兔,制备多克隆抗血清。采用ELISA检测抗血清效价,用免疫组化检测HMGB1在小鼠肝损伤组织中的表达。结果:成功构建了人HMGB1,HMGB1的Abox和Bbox原核表达载体pET28-HMGB1、pET28-Abox、pET28-Bbox,在E.coli BL21中表达,镍亲和层析柱提纯,获取纯净目的蛋白。HMGB1免疫新西兰大白兔后,抗血清效价为1:2,000,000,具有高度特异性。免疫组化显示小鼠坏死肝组织HMGB1表达增加。结论:本研究获得了人HMGB1以及HMGB1的Abox和Bbox的纯化蛋白,制备了人HMGB1的多克隆抗血清,为HMGB1的结构、组织表达谱及其功能的研究奠定了基础。     

用单因子血清识别急性致瘤性ALV诱发肿瘤组织中的fps肿瘤抗原

[目的]制备鼠抗fps单因子血清,检测急性致瘤性ALV诱发肉瘤组织中的fps肿瘤抗原.[方法]以J亚群相关禽白血病/肉瘤病毒Fu-J株RNA为模板,分两段扩增v-fps肿瘤基因,利用大肠杆菌表达系统表达这两段蛋白,纯化后将两种蛋白同时免疫小鼠,获得抗血清,间接免疫荧光试验检测肉瘤组织滤过液感染的CEF和肿瘤细胞中的fps抗原,免疫组织化学方法检测肿瘤组织中的fps抗原.[结果]该单因子血清具有较好特异性,不与经典ALV-J发生交叉反应.被感染的CEF细胞、肿瘤细胞及纤维肉瘤组织切片均显示阳性.[结论]该实验制备了鼠抗fps单因子血清,建立了fps肿瘤抗原的检测方法,为进一步研究该病毒的生物学特性及其致瘤机制奠定了基础.     

乳腺癌中Rho A蛋白表达及其与Cyclin D1和P21WAF1/CIP1蛋白表达的相关性

目的探讨Rho A蛋白在人乳腺癌中的表达情况,Rho A蛋白与临床病理因素的关系,及其与细胞周期蛋白Cyclin D1,细胞周期抑制蛋白 P21 WAF1/CIP1表达的相关性.方法应用免疫组化S-P法,检测64例乳腺癌组织及20例正常乳腺组织中Rho A蛋白、Cyclin D1和P21 WAF1/CIP1蛋白的表达情况.结果 (1)Rho A、 Cyclin D1和P21 WAF1/CIP1蛋白在正常乳腺组织中的表达率分别为5.00%、25.00%、15.00%,在乳腺癌组织中的表达率分别为73.44%、59.38%、48.44%,三者在乳腺癌组织中的阳性表达分别与正常乳腺组织相比,均差异有显著性意义(P< 0.01).(2)Rho A蛋白表达与病理组织分级,淋巴结转移相关(P< 0.05),与患者年龄、肿瘤大小及临床分期无关.(3)RhoA蛋白与P21 WAF1/CIP1蛋白表达呈负相关(χ2=4.548,P<0.05),与Cyclin D1蛋白表达无关.结论乳腺癌患者RhoA蛋白过表达与预后不良有关.RhoA蛋白通过下调P21 WAF1/CIP1蛋白参与细胞周期调节,进而与乳腺癌发展及侵袭转移相关.     

人高迁移率族蛋白B1，高迁移率族蛋白B1Abox和Bbox的原核表达、纯化及高迁移率族蛋白B1多克隆抗血清的制备

目的：获取重组人高迁移率族蛋白B1（HMGB1）,HMGB1Abox和Bbox的纯化蛋白,制备HMGB1的多克隆抗血清。方法：采用PCR方法扩增人HMGB1,HMGB1的Abox和Bbox目的基因片段,构建原核表达载体,进行原核表达与蛋白纯化,然后用HMGB1免疫新西兰大白兔,制备多克隆抗血清。采用ELISA检测抗血清效价,用免疫组化检测HMGB1在小鼠肝损伤组织中的表达。结果：成功构建了人HMGB1,HMGB1的Abox和Bbox原核表达载体pET28-HMGB1、pET28一Abox、pET28-Bbox,在E．co1iBL21中表达,镍亲和层析柱提纯,获取纯净目的蛋白。HMGB1免疫新西兰大白兔后,抗血清效价为1：2,000,000,具有高度特异性。免疫组化显示小鼠坏死肝组织HMGB1表达增加。结论：本研究获得了人HMGB1以及HMGB1的Abox和Bbox的纯化蛋白,制备了人HMGB1的多克隆抗血清,为HMGB1的结构、组织表达谱及其功能的研究奠定了基础。     

PTD融和蛋白的原核表达及其抗体制备

目的:为制备凋亡素重组蛋白抗体,首先获得凋亡素重组蛋白融合基因LTA,而且通过原核表达系统表达重组蛋白并制备其抗体,为进一步利用凋亡素重组蛋白导向治疗肿瘤的检测奠定基础.方法:应用重叠延伸的基因融合技术将LHRH(黄体生成激素释放激素)基因、TAT(HIV-1反式转录激活因子)基因和凋亡素基因重组,构建成凋亡素重组蛋白原核表达载体pET-28a-LTA,随后将表达质粒转入BL21菌株,经IPTG诱导表达重组融合蛋白,将已表达的重组蛋白通过Ni-NTA亲和色谱柱进行纯化,并制备LTA凋亡素重组蛋白抗体.结果:表达产物经聚丙烯酰胺凝胶电泳检测,LTA蛋白融合基因获得高效表达,凝胶薄层扫描分析表明表达蛋白占菌体蛋白12.6%.LTA蛋白经Ni-NTA亲和色谱柱柱纯化,以纯化蛋白为抗原免疫獭兔制备凋亡素重组蛋白抗血清.结果表明抗体的效价为1: 12800.结论:应用重叠延伸的基因融合技术获得凋亡素重组蛋白融合基因LTA,通过原核表达系统表达重组蛋白并制备其抗体.     

棉铃虫核多角体病毒iap3基因表达时相分析

目的:原核表达棉铃虫核多角体病毒(Helicoverpa armigera nucleopolyhedrovirus,HearNPV)iap3基因,制备该蛋白的多克隆抗体,并利用该抗体分析iap3基因在病毒感染过程的表达时相,为深入研究提供基础.方法:PCR扩增iap3基因后,克隆至pET28b,转化到大肠杆菌BL21 (DE3)中诱导表达,利用亲合层析进行蛋白纯化,将纯化融合蛋白免疫大鼠制备抗血清,利用抗血清Western blot检测IAP3在病毒感染过程的表达时相.结果:成功在原核细胞中表达iap3基因,并获得纯化的融合His - tag的IAP3蛋白,制备了该蛋白的多克隆抗体.发现iap3基因最早在感染后24h表达,到72h到达表达高峰.结论:获得了IAP3多克隆抗体,iaP3基因是一个晚期表达基因.     

Nuclear Translocation of hARD1 Contributes to Proper Cell Cycle Progression

Arrest defective 1 (ARD1) is an acetyltransferase that is highly conserved across organisms, from yeasts to humans. The high homology and widespread expression of ARD1 across multiple species and tissues signify that it serves a fundamental role in cells. Human ARD1 (hARD1) has been suggested to be involved in diverse biological processes, and its role in cell proliferation and cancer development has been recently drawing attention. However, the subcellular localization of ARD1 and its relevance to cellular function remain largely unknown. Here, we have demonstrated that hARD1 is imported to the nuclei of proliferating cells, especially during S phase. Nuclear localization signal (NLS)-deleted hARD1 (hARD1ΔN), which can no longer access the nucleus, resulted in cell morphology changes and cellular growth impairment. Notably, hARD1ΔN-expressing cells showed alterations in the cell cycle and the expression levels of cell cycle regulators compared to hARD1 wild-type cells. Furthermore, these effects were rescued when the nuclear import of hARD1 was restored by exogenous NLS. Our results show that hARD1 nuclear translocation mediated by NLS is required for cell cycle progression, thereby contributing to proper cell proliferation.     

凋亡素融合蛋白的可溶性表达及活性分析

目的:构建PET-28a-SPA原核表达载体,在大肠杆菌BL21(DE3)中实现其高效可溶性表达,测定对肿瘤细胞的凋亡效果。方法:本实验在获得凋亡蛋白融合基因的基础上,成功地构建了重组表达质粒PET-28a-SPA,将阳性重组质粒转化表达受体菌BL21(DE3)感受态细胞中,经IPTG诱导表达,表达产物经聚丙烯酰胺凝胶电泳检测和Western blot检测,并采用MTT法检测其对肿瘤细胞的增殖抑制。结果:表达产物经聚丙烯酰胺凝胶电泳检测,凋亡蛋白融合基因获得高效表达,软件分析表明表达蛋白占菌体蛋白20%左右。上清表达量约为10%。上清蛋白经纯化后,Western blot结果显示,利用凋亡蛋白单克隆抗体可以很好地和所表达的蛋白带特异性结合,并且对A549肺癌细胞及Hela细胞具有一定的凋亡作用。结论:所获凋亡蛋白以高效胞质可溶形式表达,为其研制有效的肿瘤免疫治疗靶向药物提供一定的基础。     

Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice

Lipid phosphate phosphatase-1 (LPP1) degrades lysophosphatidate (LPA) and attenuates receptor-mediated signaling. LPP1 expression is low in many cancer cells and tumors compared with normal tissues. It was hypothesized from studies with cultured cells that increasing LPP1 activity would decrease tumor growth and metastasis. This hypothesis has never been tested in vivo. To do this, we inducibly expressed LPP1 or a catalytically inactive mutant in cancer cells. Expressing active LPP1 increased extracellular LPA degradation by 5-fold. It also decreased the stimulation of Ca²⁺ transients by LPA, a nondephosphorylatable LPA_1/2 receptor agonist and a protease-activated receptor-1 peptide. The latter results demonstrate that LPP1 has effects downstream of receptor activation. Decreased Ca²⁺ mobilization and Rho activation contributed to the effects of LPP1 in attenuating the LPA-induced migration of MDA-MB-231 breast cancer cells and their growth in 3D culture. Increasing LPP1 expression in breast and thyroid cancer cells decreased tumor growth and the metastasis by up to 80% compared with expression of inactive LPP1 or green fluorescent protein in syngeneic and xenograft mouse models. The present work demonstrates for the first time that increasing the LPP1 activity in three lines of aggressive cancer cells decreases their abilities to produce tumors and metastases in mice.     

Expression, purification, and characterization of functional recombinant human daintain/AIF-1 in Escherichia coli

Daintain/AIF-1 was identified from injured rat carotid arteries and porcine intestine in the mid 1990s. It is involved in autoimmune disorders, chronic rejection of allografts, gliomas, and breast cancer. Since it is convenient and economical to obtain such a peptide biologically, in this study, we describe the expression, purification, and characterization of recombinant human daintain/AIF-1 (rhdaintain/AIF-1). The backbone of vector pET32a, a high-level expression plasmid, was used to construct the pET32a-daintain/AIF-1 plasmid for daintain/AIF-1 expression in Escherichia coli. The recombinant daintain/AIF-1 protein was solubly expressed in the BL21 (DE3) strain and was purified by Ni2+ affinity chromatography. After purification, the recombinant protein showed the expected size of 18 kDa on Tricine-SDS-PAGE gels which was further confirmed by Western blotting. A total of 34.0 mg of high purity (over 98%) rhdaintain/AIF-1 was obtained from 1 L culture. The recombinant peptide was able to increase blood glucose elimination rates and enhance the proliferation of human MCF-7 cells. These results suggest that biological activity of the recombinant peptide was preserved after purification.     

鸽β-防御素1基因的克隆及其生物学作用鉴定

【目的】从鸽子组织中克隆鸽子β-防御素1(AvBD1)基因,在大肠杆菌中表达重组鸽子AvBD1蛋白,测定其生物学特性。【方法】应用RT-PCR法从鸽子骨髓组织中扩增鸽子AvBD1基因,采用Real-time PCR法检测该基因在鸽子组织器官中的表达分布。将该基因亚克隆到大肠杆菌原核表达载体pProEX-HTa的EcoR I和Xho I双酶切位点上,构建重组表达质粒pProEX-pigeon AvBD1,将重组质粒进行诱导表达;对该重组蛋白进行纯化,通过菌落计数法测定其体外抗菌活性与理化特性。【结果】从鸽子骨髓组织中克隆到鸽子AvBD1基因,其cDNA大小为198 bp,编码65个氨基酸,经序列相似性分析,鸽子AvBD1与鸭AvBD1氨基酸序列相似性最高(81.5%)。鸽子AvBD1主要分布于免疫系统和消化系统组织中。Tricine-SDS-PAGE电泳结果表明,重组鸽子AvBD1蛋白分子量约8.8 kD,与预期大小一致。该重组蛋白具有广谱抗菌活性,高盐浓度显著降低其抗菌活性。此外,该重组蛋白的溶血活性极低。【结论】从鸽子骨髓组织中克隆到鸽子AvBD1基因,其主要分布在机体的免疫系统和消化系统中。该重组蛋白具有广谱抗菌活性,高盐浓度显著降低其抗菌活性,且该重组蛋白的溶血活性极低。     

人SCYL1-BP1重组蛋白的原核表达及分离纯化鉴定

前期研究结果发现,SCYL1-BP1具有细胞周期调控功能,同时具有肿瘤抑制因子的特性。目的:采用基因工程技术,构建SCYL1-BP1的大肠杆菌重组表达菌株,以获得足够量的高纯度目的蛋白,为后面进行一系列药理学检测及新药安全性测试奠定基础。方法:利用从人胎脑cDNA文库中克隆得到SCYL1-BP1基因克隆为模板,经PCR扩增,通过酶切位点克隆到新型原核表达载体pET-28b-SUMO上,转化大肠杆菌表达菌BL21(DE3)。经IPTG诱导表达,摸索优化表达条件,表达产物经Ni柱进行亲和层析纯化,后再进行SDS-PAGE和Western blot等分析鉴定。结果:成功构建了SCYL1-BP1的原核表达工程菌BL21(DE3)/pET-28b-SUMO-SCYL1BP1。SDS-PAGE和Western blot检验结果表明,诱导表达的融合蛋白His6-SUMO-SCYL1BP1的分子量约为65 kDa,主要以可溶的形式存在,且能被His标签抗体和SCYL1-BP1单克隆抗体特异性识别。结论:原核表达并纯化了人SCYL1-BP1融合蛋白,为其后续功能研究及性质实验奠定基础。     

Purification and characterization of human cell--cell adhesion molecule 1 (C-CAM1) expressed in insect cells

The cell--cell adhesion molecule 1 (C-CAM1) plays an important role as a tumor suppressor for prostate cancer. Decreased expression of C-CAM1 was detected in prostate, breast, and colon carcinoma. Reexpression of C-CAM1 in prostate and breast cancer cell lines was able to suppress tumorigenicity in vivo. These observations suggest that C-CAM1 may be used as a marker for cancer detection or diagnosis. To generate monoclonal antibodies specific to C-CAM1, we have overexpressed full-length human C-CAM1 in Sf9 cells using a baculovirus expression system. The protein was purified 104-fold using nickel affinity chromatography. About 0.4 mg purified C-CAM1 was obtained from 200 mg of infected cells. When the purified protein was digested with peptidyl-N-glycosidase, the apparent mobility of the protein on SDS--PAGE changed from 90 to 58 kDa, which is close to the molecular weight predicted from the cloned cDNA sequence. This observation suggests that C-CAM1 was glycosylated on asparagine residues when expressed in Sf9 cells. Western blotting and internal protein sequencing analysis confirmed that the purified protein is human C-CAM1. Biochemical and functional assays indicate that this protein expressed in Sf9 cells displays characteristics similar to those of native protein, including adhesion function and glycosylation modification. Using this protocol, sufficient quantity of this protein can be produced with purity suitable for monoclonal antibody generation and biochemical study.     

人类抑癌基因beclin 1在胃癌和直结肠癌中表达下调的研究

人类抑癌基因beclin 1通过自噬作用调节细胞生长,但在胃癌和直结肠癌中其表达水平和调控机制仍不清楚．通过检测胃癌和直结肠肿瘤组织中beclin 1基因的表达水平,及DNA异常甲基化和杂合子缺失对其表达的影响,发现与癌旁组织相比,35％的胃癌标本和30％的直结肠癌标本中beclin 1基因表达显著下调．同时发现,beclin 1基因5’端存在一高密度CpG岛,在胃癌和直结肠癌中beclin 1的启动子区域和第二个内含子区域存在甲基化,而杂合子缺失仅在胃癌中发生．这些发现表明beclin 1基因的异常甲基化和杂合子缺失对其在胃癌和直结肠癌中的表达起调控作用．     

Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors

Apoptosis-inducing ligands such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have been found to play an important role in cell regulation. Different malignant tumors show an altered expression of these ligands and their respective receptors compared to normal tissues. The purpose of this study was therefore to investigate expression of TRAIL, FasL, and its receptor Fas on protein and mRNA levels in breast carcinomas (n=40), fibroadenomas (n=7), and normal breast tissues (n=5). Immunohistochemical reaction demonstrated that FasL was strongly expressed in breast cancer tissues (34/40) while only one fibroadenoma and one normal breast tissue reacted weakly positive for FasL. All fibroadenomas and normal breast tissues as well as the majority of breast cancer tissues expressed Fas on protein level. Quantitative RT-PCR analysis detected high expression of FasL mRNA in breast cancer tissues and fibroadenomas, whereas fibroadenomas showed the highest Fas mRNA copy numbers, followed by breast cancer tissues and normal breast tissues (P<0.05). Compared to FasL expression, TRAIL could be detected in less breast cancer tissues on protein level (21/40) and was found in only one fibroadenoma and none of the normal breast tissues. Thus, it can be concluded that malignant breast tumors show an altered expression of the two apoptosis-inducing ligands FasL and TRAIL. Accepted: 4 January 2000